Form 8-K - Current report:
SEC Accession No. 0001104659-25-102104
Filing Date
2025-10-24
Accepted
2025-10-24 15:26:23
Documents
14
Period of Report
2025-10-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2529425d2_8k.htm   iXBRL 8-K 29986
2 EXHIBIT 5.1 tm2529425d2_ex5-1.htm EX-5.1 10662
6 GRAPHIC tm2529425d2_ex5-1img001.jpg GRAPHIC 3127
  Complete submission text file 0001104659-25-102104.txt   216001

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20251024.xsd EX-101.SCH 3041
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20251024_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20251024_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2529425d2_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 251415924
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)